Prostatype Genomics AB announces today that the company is changing its Certified Adviser to Tapper Partners AB.
Prostatype Genomics AB has entered into an agreement with Tapper Partners AB regarding the role as Certified Adviser.
Tapper Partners AB will assume the role of Certified Adviser on August 15, 2025. Until then, DNB Carnegie Investment Bank AB will continue to act as the company's Certified Adviser.